JP Morgan Chase’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.5B Sell
12,598,524
-1,099,967
-8% -$1.12B 0.86% 15
2026
Q1
$12.1B Buy
13,698,491
+700,545
+5% +$710M 0.78% 18
2025
Q4
$14B Buy
12,997,946
+2,729,791
+27% +$2.61B 0.88% 13
2025
Q3
$7.83B Sell
10,268,155
-2,242,818
-18% -$1.67B 0.47% 29
2025
Q2
$9.75B Sell
12,510,973
-968,945
-7% -$753M 0.64% 22
2025
Q1
$11.1B Sell
13,479,918
-1,434,822
-10% -$1.19B 0.81% 17
2024
Q4
$11.5B Sell
14,914,740
-3,351,381
-18% -$2.77B 0.86% 13
2024
Q3
$16.2B Sell
18,266,121
-597,405
-3% -$537M 1.23% 7
2024
Q2
$17.1B Sell
18,863,526
-387,439
-2% -$310M 1.4% 8
2024
Q1
$15B Sell
19,250,965
-152,568
-0.8% -$109M 1.27% 7
2023
Q4
$11.3B Buy
19,403,533
+3,600,341
+23% +$2.1B 1.08% 10
2023
Q3
$8.49B Buy
15,803,192
+1,663,578
+12% +$857M 0.94% 11
2023
Q2
$6.63B Buy
14,139,614
+3,228,109
+30% +$1.35B 0.72% 15
2023
Q1
$3.75B Sell
10,911,505
-5,108,156
-32% -$1.72B 0.46% 41
2022
Q4
$5.86B Buy
16,019,661
+1,261,226
+9% +$447M 0.77% 14
2022
Q3
$4.77B Sell
14,758,435
-736,640
-5% -$233M 0.69% 18
2022
Q2
$5.02B Sell
15,495,075
-801,157
-5% -$240M 0.7% 15
2022
Q1
$4.67B Sell
16,296,232
-701,646
-4% -$181M 0.56% 24
2021
Q4
$4.7B Buy
16,997,878
+1,312,944
+8% +$333M 0.54% 28
2021
Q3
$3.62B Sell
15,684,934
-1,458,083
-9% -$360M 0.45% 36
2021
Q2
$3.93B Sell
17,143,017
-189,805
-1% -$38.1M 0.47% 33
2021
Q1
$3.24B Sell
17,332,822
-4,183,822
-19% -$818M 0.43% 39
2020
Q4
$3.63B Buy
21,516,644
+2,674,219
+14% +$399M 0.53% 29
2020
Q3
$2.76B Buy
18,842,425
+2,900,041
+18% +$449M 0.46% 37
2020
Q2
$2.62B Sell
15,942,384
-1,413,825
-8% -$217M 0.51% 34
2020
Q1
$2.41B Sell
17,356,209
-1,286,604
-7% -$177M 0.57% 30
2019
Q4
$2.45B Buy
18,642,813
+3,091,191
+20% +$358M 0.46% 38
2019
Q3
$1.74B Sell
15,551,622
-1,202,202
-7% -$134M 0.35% 56
2019
Q2
$1.87B Sell
16,753,824
-1,235,003
-7% -$145M 0.37% 50
2019
Q1
$2.33B Buy
17,988,827
+492,845
+3% +$59.9M 0.48% 37
2018
Q4
$2.02B Sell
17,495,982
-762,101
-4% -$85.1M 0.47% 31
2018
Q3
$1.96B Sell
18,258,083
-1,129,206
-6% -$113M 0.38% 44
2018
Q2
$1.65B Buy
19,387,289
+3,438,532
+22% +$282M 0.34% 54
2018
Q1
$1.23B Sell
15,948,757
-3,172,646
-17% -$255M 0.26% 73
2017
Q4
$1.61B Sell
19,121,403
-1,489,076
-7% -$127M 0.34% 51
2017
Q3
$1.75B Sell
20,610,479
-261,613
-1% -$21.5M 0.39% 42
2017
Q2
$1.72B Sell
20,872,092
-15,272
-0.1% -$1.25M 0.39% 42
2017
Q1
$1.76B Sell
20,887,364
-143,380
-0.7% -$11.5M 0.4% 41
2016
Q4
$1.55B Sell
21,030,744
-216,932
-1% -$16.2M 0.37% 45
2016
Q3
$1.71B Sell
21,247,676
-1,936,940
-8% -$155M 0.42% 37
2016
Q2
$1.83B Buy
23,184,616
+671,416
+3% +$50.5M 0.46% 36
2016
Q1
$1.62B Sell
22,513,200
-1,235,173
-5% -$93.5M 0.42% 40
2015
Q4
$2B Sell
23,748,373
-468,119
-2% -$38.8M 0.5% 31
2015
Q3
$2.03B Buy
24,216,492
+9,191,485
+61% +$776M 0.54% 29
2015
Q2
$1.25B Buy
15,025,007
+7,743,373
+106% +$590M 0.3% 61
2015
Q1
$529M Buy
7,281,634
+422,104
+6% +$30.1M 0.12% 190
2014
Q4
$473M Buy
6,859,530
+13,290
+0.2% +$897K 0.11% 205
2014
Q3
$444M Sell
6,846,240
-542,120
-7% -$34.3M 0.11% 220
2014
Q2
$459M Buy
7,388,360
+1,089,684
+17% +$65M 0.12% 198
2014
Q1
$371M Buy
6,298,676
+150,809
+2% +$8.42M 0.1% 218
2013
Q4
$314M Sell
6,147,867
-1,355,913
-18% -$67.9M 0.09% 248
2013
Q3
$378M Sell
7,503,780
-432,779
-5% -$22.7M 0.11% 216
2013
Q2
$390M Buy
+7,936,559
New +$432M 0.12% 194

Other funds holding LLY

JP Morgan Chase's LLY Position: Q2 2026 in Review

JP Morgan Chase reduced its Eli Lilly (LLY) stake by 8% in Q2 2026, selling an estimated $1.12B and leaving 12,598,524 shares worth $15.5B. The position accounts for 0.86% of the portfolio, ranked #15.

JP Morgan Chase first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. The position peaked at $17.1B in Q2 2024. 4,593 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • JP Morgan Chase held 12,598,524 shares of Eli Lilly worth $15.5B as of Q2 2026.
  • JP Morgan Chase sold 1,099,967 Eli Lilly shares in Q2 2026, an estimated $1.12B.
  • Eli Lilly made up 0.86% of JP Morgan Chase's portfolio in Q2 2026, its #15 holding.
  • JP Morgan Chase first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Eli Lilly position peaked at $17.1B in Q2 2024.
  • 4,593 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.